Stock RCUS ARCUS BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 21:00:02 01/05/2024 BST 		5-day change 1st Jan Change
15.5 USD +1.77% Intraday chart for Arcus Biosciences, Inc. +0.45% -18.85%
03-12 Transcript : Arcus Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
02-29 Arcus Biosciences Insider Sold Shares Worth $1,177,967, According to a Recent SEC Filing MT

Business Summary

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Number of employees: 577

Sales per Business

USD in Million2022Weight2023Weight Delta
Immunotherapies
100.0 %
112 100.0 % 117 100.0 % +4.46%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
112 100.0 % 117 100.0 % +4.46%

Managers

Managers TitleAgeSince
Juan Jaen FOU
 Founder 66 31/12/14
Terry Rosen CEO
 Chief Executive Officer 64 31/12/14
Robert Goeltz DFI
 Director of Finance/CFO 51 31/07/20
Dimitry Nuyten CTO
 Chief Tech/Sci/R&D Officer - 31/07/22
Steve Young CTO
 Chief Tech/Sci/R&D Officer 55 29/02/16
Jennifer Jarrett COO
 Chief Operating Officer 53 28/02/17
Jonathan Yingling CTO
 Chief Tech/Sci/R&D Officer 55 31/12/19
Eric Matthews PRN
 Corporate Officer/Principal - 23/06/19
Alexander Azoy AUD
 Comptroller/Controller/Auditor 48 01/10/20
Carolyn Tang LAW
 General Counsel 45 30/06/17

Members of the board

Members of the board TitleAgeSince
Terry Rosen CEO
 Chief Executive Officer 64 31/12/14
Kathryn Falberg BRD
 Director/Board Member 63 17/09/17
Yasunori Kaneko BRD
 Director/Board Member 69 30/04/15
Juan Jaen FOU
 Founder 66 31/12/14
Merdad Parsey BRD
 Director/Board Member 61 12/07/20
Antoni Ribas BRD
 Director/Board Member 57 27/10/19
David Lacey BRD
 Director/Board Member 71 20/05/20
Nicole Lambert BRD
 Director/Board Member 50 02/08/21
Jennifer Jarrett COO
 Chief Operating Officer 53 28/02/17
Johanna Mercier BRD
 Director/Board Member 54 01-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 90,952,836 53,540,725 ( 58.87 %) 0 58.87 %

Shareholders

NameEquities%Valuation
GILEAD SCIENCES, INC.
34.70 %
31,532,781 34.70 % 595 M $
BlackRock Advisors LLC
10.46 %
9,504,562 10.46 % 179 M $
Fidelity Management & Research Co. LLC
5.204 %
4,728,782 5.204 % 89 M $
Vanguard Fiduciary Trust Co.
5.151 %
4,680,716 5.151 % 88 M $
STATE STREET CORPORATION
4.666 %
4,239,577 4.666 % 80 M $
Terry Rosen
4.366 %
3,966,974 4.366 % 75 M $
Octagon Capital Advisors LP
2.056 %
1,868,000 2.056 % 35 M $
Ameriprise Trust Co.
1.799 %
1,634,805 1.799 % 31 M $
Invus Financial Advisors LLC
1.774 %
1,612,077 1.774 % 30 M $
Boxer Capital LLC
1.763 %
1,602,200 1.763 % 30 M $

Company contact information

Arcus Biosciences, Inc.

3928 Point Eden Way

94545, Hayward

+

http://www.arcusbio.com
address Arcus Biosciences, Inc.(RCUS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Arcus Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.5 USD
Average target price
38.89 USD
Spread / Average Target
+150.90%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARCUS BIOSCIENCES, INC. Stock Arcus Biosciences, Inc.
-18.85% 1.41B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.95B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 11.32B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RCUS Stock
  4. Company Arcus Biosciences, Inc.